Abstract

Background: This study evaluated the relationship between preoperative neutrophil / lymphocyte ratio - platelet / lymphocyte ratio, clinicopathological, radiological factors, and axillary lymph node metastasis in stage I-III breast cancer to determine if axillary surgery can be safely omitted in selected patients.

Methods: The study included 158 Stage I-III breast cancer patients operated on at Baskent University Zubeyde Hanim Research Center between 2011 and 2018. The incidence of axillary lymph node metastasis was correlated with clinical, radiological, pathological, and laboratory (neutrophil count to lymphocyte count, platelet count to lymphocyte count) findings by univariate and multivariate analyses. Sensitivity and specificity calculations, positive predictive value, negative predictive value, positive and negative Likelihood Ratio (accuracy ratio), and exact accuracy were calculated for neutrophil/lymphocyte ratio cut-off values of 3.5 and 1.

Results: Neutrophil and platelet values were significantly higher in patients with lymph node metastasis. Neutrophil / lymphocyte ratio - platelet / lymphocyte ratio values were higher in patients with axillary lymph node metastasis, but this was not statistically significant. Axillary lymph node metastasis was not associated with age, lymphocyte, monocyte count, estrogen receptor, progesterone receptor, or c-erb B2 status. The incidence of axillary lymph node metastasis was statistically significantly higher in the presence of lymphovascular invasion. Sensitivity, specificity, positive predictive value, and negative predictive value were 93.85%, 16.67%, 44.9%, and 78.9% respectively for axillary lymph node metastasis while the neutrophil / lymphocyte ratio was ≥ 3.5. Specificity, sensitivity, positive predictive value, and negative predictive value were 97.78%, 9.23%, 75.0%, and 59.9% respectively for axillary lymph node metastasis while the neutrophil / lymphocyte ratio < 1.

Conclusions: For axillary lymph node metastasis, neutrophil, platelet counts, lymphovascular invasion status, radiological and pathological mass size, and presence of radiological axillary lymphadenopathy are the statistically significant independent variables. They provide information that can help surgeons decide on the treatment of breast cancer patients with specific neutrophil / lymphocyte ratio values (neutrophil / lymphocyte ratio < 1 and neutrophil / lymphocyte ratio ≥ 3.5).

Keywords: Neutrophil / Lymphocyte Ratio; Trombocyte / Lymphocyte Ratio; Lymph Node Metastasis; Breast Cancer

References

1. Giuliano AE., et al. “Lokoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial”. Annals of Surgery 252 (2010): 426-432.
2. Veronesi U., et al. “Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomised controlled study”. The Lancet Oncology 7 (2006): 983-990.
3. Krag DN., et al. “Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial”. The Lancet Oncology 11 (2010): 927-933.
4. Ashikaga T., et al. “Bowel Project (2010) Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection”. Journal of Surgical Oncology 102 (2010):111-118. 
5. Lucci A., et al. “American College of Surgeons Oncology Group (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in American College of Surgeons Oncology Group Trial Z0011”. Journal of Clinical Oncology 25 (2007): 3657-3663. 
6. Lal I., et al. “Platelets, coagulation and fibrinolysis in breast cancer progression”. Breast Cancer Research 15.4 (2013): 207.
7. Guthrie GJ., et al. “The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer”. Critical Reviews in Oncology/Hematology 88.1 (2013): 218-230. 
8. Azab B., et al. “Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients”. Annals of Surgical Oncology 19.1 (2012): 217-224. 
9. Templeton AJ., et al. “Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis”. Journal of the National Cancer Institute 106.6 (2014): 124. 
10. Mantovani A., et al. “Cancer-related inflammation”. Nature 454.7203 (2008): 436-444. 
11. Koh CH., et al. “Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer”. British Journal of Cancer 113.1 (2015): 150-158. 
12. Cihan YB., et al. “Lack of prognostic value of blood parameters in patients receiving adjuvant radiotherapy for breast cancer”. Asian Pacific Journal of Cancer Prevention 15.10 (2014):4225-4231.
13. Ulas A., et al. “Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?” Journal of BUON 20.3 (2015): 714-722.
14. Chua B., et al. “Frequency and predictors of axillary lymph node metastases in invasive breast cancer”. ANZ Journal of Surgery 71.12 (2001): 723-728.
15. Yilmaz TH., et al. “Diagnostic Accuracy of Axillary Ultrasound in Early–Stage Breast Cancer”. Indian Journal of Surgery (2018).

Citation

Citation: Tugba Han Öner., et al. “Neutrophil / Lymphocyte Ratio (NLR) – Trombocyte / Lymphocyte Ratio (TLR): A Predictor of Axillary Lymph Node Metastasis in Breast Cancer Patients?". Acta Scientific Medical Sciences 4.2 (2020): 115-121.

Copyright

Copyright: © 2020 Tugba Han Öner., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.